Viracta Therapeutics's total assets for Q1 2024 were $41.33M, a decrease of -27.09% from the previous quarter. VIRX total liabilities were $30.25M for the fiscal quarter, a -21.16% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.